公开(公告)号：US20170020939A1

公开(公告)日：2017-01-26

申请号：US15302300

申请日：2015-04-08

申请人： euglena Co., Ltd.

发明人： Ayaka NAKASHIMA ,  Yuta ASAYAMA ,  Eriko YOSHIDA ,  Osamu IWATA ,  Kengo SUZUKI

IPC分类号： A61K36/02 ,  A23L33/10 ,  A61K31/715

CPC分类号： A61K36/02 ,  A23L33/10 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/715 ,  A61K31/716 ,  C12N1/10

摘要： The present invention provides a novel immune balance regulator that regulates an immune balance in a living body. The immune balance regulator contains a Euglena-derived material and regulates an immune balance between Th1, Th2, and Th17, which is a balance between immune responses individually induced by Th1, Th2, and Th17 in a living body. The immune balance regulator regulates the immune balance between Th1, Th2, and Th17 so that immune responses induced by Th1 become relatively dominant over immune responses induced by Th2 or Th17 to improve a physical constitution that has an immune imbalance of Th1, Th2, and Th17 shifted towards Th2 and to prevent or treat a disease associated with the immune imbalance of Th1, Th2, and Th17 shifted towards a Th2 dominance. The immune balance regulator is administered prior to expected onset of a disease associated with the immune imbalance of Th1, Th2, and Th17 shifted towards the Th2 dominance.

摘要翻译： 本发明提供了调节活体免疫平衡的新型免疫平衡调节剂。 免疫平衡调节物含有来自Euglena的材料并调节Th1，Th2和Th17之间的免疫平衡，Th1，Th2和Th17是活体中Th1，Th2和Th17单独诱导的免疫反应之间的平衡。 免疫平衡调节因子调节Th1，Th2和Th17之间的免疫平衡，使Th1诱导的免疫反应相对于由Th2或Th17诱导的免疫应答相对优势，以改善具有Th1，Th2和Th17免疫失衡的物理结构 转移到Th2，并预防或治疗与Th1，Th2和Th17的免疫不平衡相关的疾病向Th2优势转移。 免疫平衡调节剂在预期发生与Th1，Th2和Th17的免疫失衡相关的疾病之前施用，向Th2优势移动。

公开(公告)号：US20180133271A1

公开(公告)日：2018-05-17

申请号：US15563993

申请日：2016-04-07

申请人： euglena Co., Ltd.

发明人： Ayaka NAKASHIMA ,  Yuta ASAYAMA ,  Osamu IWATA ,  Kengo SUZUKI

IPC分类号： A61K36/05 ,  A23L33/10 ,  A61P19/02

摘要： Provided are an inhibitor, a prophylactic, and a therapeutic agent for rheumatoid arthritis that have no side effects and that can correct immune abnormality associated with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent for rheumatoid arthritis contain a Euglena-derived material as an active ingredient. The inhibitor, the prophylactic and the agent are used as an antirheumatic drug for controlling the activity of rheumatoid arthritis by alleviating immune abnormality associated with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent are also used for a living individual who has not been definitively diagnosed with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent are continuously administered to the living individual from any point before definitive diagnosis of rheumatoid arthritis to any point after the definitive diagnosis. The Euglena-derived material is at least one material selected from the group including Euglena algae, paramylon derived from the Euglena, water-soluble amorphous paramylon prepared by treating the paramylon with alkali and neutralizing the treated paramylon, and emulsion paramylon prepared by ejecting a solution of the paramylon from a narrow bore nozzle at a very high pressure to cause the solution to collide with a collision surface.

公开(公告)号：US20170319632A1

公开(公告)日：2017-11-09

申请号：US15524522

申请日：2015-11-06

申请人： euglena Co., Ltd.

发明人： Eriko YOSHIDA ,  Yuta ASAYAMA ,  Osamu IWATA ,  Ayaka NAKASHIMA ,  Kengo SUZUKI ,  Misa OHGUSHI ,  Naoki HARADA ,  Yoshihisa NAKANO

IPC分类号： A61K35/68 ,  A61K31/716

CPC分类号： A61K35/68 ,  A61K31/716

摘要： Provided are a prophylactic or therapeutic agent for a peptic ulcer, a food additive for prevention and treatment of a peptic ulcer, an iNOS expression inhibitor, and a COX-2 expression inhibitor, all of which have little side effects. The prophylactic or therapeutic agent contains a Euglena-derived material as an active ingredient. The Euglena-derived material may be Euglena, paramylon, or an acid-treated paramylon. The prophylactic or therapeutic agent is useful for the prevention or treatment of a peptic ulcer induced by psychological stress. The peptic ulcer may be a gastric ulcer. The food additive contains a Euglena-derived material as an active ingredient.

公开(公告)号：US20170224717A1

公开(公告)日：2017-08-10

申请号：US15514966

申请日：2015-09-29

申请人： Euglena Co., Ltd.

发明人： Ayaka NAKASHIMA ,  Yuta ASAYAMA ,  Osamu IWATA ,  Kengo SUZUKI

IPC分类号： A61K31/716

CPC分类号： A61K31/716 ,  A61K31/718

摘要： Provided are a novel renal failure progression inhibitor, prophylactic agent for renal failure, and indoxyl sulfate production inhibitor, intended for human use, in particular, for a patient with renal failure. The renal failure progression inhibitor, prophylactic agent for renal failure, and indoxyl sulfate production inhibitor each comprises paramylon derived from Euglena or a processed product thereof as an active ingredient. In the case of the renal failure progression inhibitor, for example, paramylon is continuously orally administered to a patient suffering from chronic renal failure, undergoing a dialysis therapy, several times per day in a dose of 1 to 5 g per intake. In particular, the renal failure progression inhibitor is singly administered to the patient in a capsule or powdered preparation at a prescribed time interval before and after administration of other drugs.